ReviewInternational urology and nephrology2016
Metabonomic biomarkers for risk factors of chronic kidney disease.
Review in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Global, regional, and national burdens of chronic kidney disease attributable to high body mass index from 1990 to 2021, with future forecasts up to 2050: a systematic analysis for the global burden of disease study 2021.Frontiers in public health · 2025Article
- Shenkang Injection for Treating Renal Fibrosis-Metabonomics and Regulation of E3 Ubiquitin Ligase Smurfs on TGF-β/Smads Signal Transduction.Frontiers in pharmacology · 2022Article
- Plasma metabolomic profiling reveals factors associated with dose-adjusted trough concentration of tacrolimus in liver transplant recipients.Frontiers in pharmacology · 2022Article
- Plasma metabolites associated with chronic kidney disease and renal function in adults from the Baltimore Longitudinal Study of Aging.Metabolomics : Official journal of the Metabolomic Society · 2021Article
- Metabolomics Analysis Reveals the Protection Mechanism of Huangqi-Danshen Decoction on Adenine-Induced Chronic Kidney Disease in Rats.Frontiers in pharmacology · 2019Article
- NMR-based urine metabolic profiling and immunohistochemistry analysis of nephron changes in a mouse model of hypoxia-induced acute kidney injury.American journal of physiology. Renal physiology · 2018Article
- Protection Effect of Exogenous Fibroblast Growth Factor 21 on the Kidney Injury in Vascular Calcification Rats.Chinese medical journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChronic kidney disease, characterized by gradual loss of renal function and irreversible progression, is becoming a major public health problem worldwide. Chronic kidney disease may lead to end-stage renal disease, as well as increase the morbidity and mortality associated with cardiovascular disease.
methodsThis review focuses on identifying risk factors indicating the need for intervention in early stages of chronic kidney disease, as well as determining factors that may improve patient prognosis. However, all the risk factors giving rise to the progression of chronic kidney disease have not yet been identified.
resultsMetabonomics is a new type of omics that reflects the real-time pathophysiology of disease and focuses on endogenous metabolites of low molecular weight. This new and powerful tool has recently been used to explore metabonomic biomarkers of chronic kidney disease, enabling early diagnosis and timely intervention and treatment to slow the progression of chronic kidney disease.
conclusionsThis review summarizes recent findings on the identification, using a metabonomic approach, of biomarkers associated with risk factors for the development and progression of chronic kidney disease.
Indexed as
Identifiers
26897037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.